CDXC looks like a good chart heregood price action
currently consolidating here
all indicators look primed.
The chart patterns are aligned. good price action
currently consolidating here
all indicators look primed.
The chart patterns are aligned
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.02USD
−4.94 MUSD
83.57 MUSD
47.93 M
About ChromaDex Corporation
Sector
CEO
Robert N. Fried
Headquarters
Los Angeles
Website
Founded
1999
FIGI
BBG000BG1J71
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
CDXC (POTENTIAL BUY LEVEL) ***BULLISH SENTIMENT This is just my basic MONTHLY charting.
I have marked what I see as the POSSIBLE bottom (support).
I see overall DOWNTREND with possible reversal.
I have marked my potential BUY LEVELS for LONGS//CALLS.
CDXC: Breakout Confirmed, 41.8% Potential Profit!Description: CDXC is trending higher and in an uptrend meaning that highs are getting higher and lows are getting higher. The uptrend line on the chart and the Trending Band Indicator (which measures trend) supports the Long Position.
Stats:
1. Ideal buy range: $7.5 - $8.2
2. Take profit: $11.02
3.
Reduced recovery time in mild-to-moderate COVID-19 patientsNew Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients
The addition of the nutritional pro
CDXC: Bullish PennantBullish Pennant
Pros:
Descending volume during formation
PPS above 50MA and 200MA
RS above 0, and ascending
ATR Ascending
R/R ratio above 8
250RSI above 50
200MA ascending
Cons:
Volume during formation
Target:
PT = 14.94$
1000 Followers! Thank you all!
Thank you to those who donate Coins!
Stay Hum
CDXC running towards 10 with impressive volumesAs one of few micro-cap with real revenues (40% growth) blessed with huge market potential and very competent managment, I suspect the company will be bought out by one of the SPACs with too much cash but no real business. Patience is likely to be rewarded handsomely.
Volumes have been tripling fo
CDXC: Small Float Biopharma with BIG Potential $20After basing for many years, CDXC is showing signs of awakening. Stocks are being accumulated but not aggressively. It's one of few bio stocks with insider buying at the current price.
The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap,
CDXC 4.8: Small Float Biotech backed by Li Ka Shing In this market where SPEC trades at billions with NO revenue, I like CDXC though I may be early. Yes it's not TSLA, yes Value does not work in this market but
With a tiny market cap of 290 mil and revenue growth at 40% (still early-stage market), I am betting with Li Ka Shing, one of the richest a
CDXC Chromadex Corp Upside TaregtsChromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment of
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CDXC is 5.86 USD — it has increased by 67.91% in the past 24 hours. Watch ChromaDex Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ChromaDex Corporation stocks are traded under the ticker CDXC.
CDXC stock has risen by 69.86% compared to the previous week, the month change is a 66.95% rise, over the last year ChromaDex Corporation has showed a 340.60% increase.
We've gathered analysts' opinions on ChromaDex Corporation future price: according to them, CDXC price has a max estimate of 9.00 USD and a min estimate of 6.00 USD. Watch CDXC chart and read a more detailed ChromaDex Corporation stock forecast: see what analysts think of ChromaDex Corporation and suggest that you do with its stocks.
CDXC reached its all-time high on Feb 25, 2021 with the price of 23.66 USD, and its all-time low was 0.33 USD and was reached on Aug 3, 2009. View more price dynamics on CDXC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CDXC stock is 65.01% volatile and has beta coefficient of 0.45. Track ChromaDex Corporation stock price on the chart and check out the list of the most volatile stocks — is ChromaDex Corporation there?
Today ChromaDex Corporation has the market capitalization of 265.01 M, it has increased by 4.37% over the last week.
Yes, you can track ChromaDex Corporation financials in yearly and quarterly reports right on TradingView.
ChromaDex Corporation is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
CDXC earnings for the last quarter are 0.03 USD per share, whereas the estimation was 0.01 USD resulting in a 414.43% surprise. The estimated earnings for the next quarter are 0.01 USD per share. See more details about ChromaDex Corporation earnings.
ChromaDex Corporation revenue for the last quarter amounts to 25.58 M USD, despite the estimated figure of 24.03 M USD. In the next quarter, revenue is expected to reach 25.96 M USD.
CDXC net income for the last quarter is 1.88 M USD, while the quarter before that showed −15.00 K USD of net income which accounts for 12.62 K% change. Track more ChromaDex Corporation financial stats to get the full picture.
No, CDXC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 2, 2024, the company has 106.00 employees. See our rating of the largest employees — is ChromaDex Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ChromaDex Corporation EBITDA is 5.15 M USD, and current EBITDA margin is −0.23%. See more stats in ChromaDex Corporation financial statements.
Like other stocks, CDXC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ChromaDex Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ChromaDex Corporation technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ChromaDex Corporation stock shows the strong buy signal. See more of ChromaDex Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.